Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 105

Sort by

Sort Order Select

Journal Articles

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

Blood (2024) 144 (10): 1083–1092.

https://doi.org/10.1182/blood.2024023962

Published: 2024

Includes: Supplemental data

Journal Articles

Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma

Blood (2022) 140 (Supplement 1): 6489–6491.

https://doi.org/10.1182/blood-2022-167633

Published: 2022

Journal Articles

Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis

Blood (2022) 140 (Supplement 1): 9882–9884.

https://doi.org/10.1182/blood-2022-168152

Published: 2022

Journal Articles

Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting

Blood (2022) 140 (Supplement 1): 6517–6519.

https://doi.org/10.1182/blood-2022-165419

Published: 2022

Journal Articles

Day 100 Peripheral Blood Natural Killer Cell/CD14+HLA-DR - Ratio Predicts Clinical Outcomes in Lymphoma Patients Treated with Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation

Luis F. Porrata, David J. Inwards, Stephen M. Ansell, Ivana N. Micallef, Patrick B. Johnston, Jose C. Villasboas, Jonas Paludo, Urshila Durani, Svetomir N. Markovic

Blood (2022) 140 (Supplement 1): 10577–10578.

https://doi.org/10.1182/blood-2022-163724

Published: 2022

Journal Articles

Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411

Blood (2022) 140 (Supplement 1): 186–188.

https://doi.org/10.1182/blood-2022-170381

Published: 2022

Journal Articles

PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts

Sanjal H Desai, Levi D. Pederson, Betsy Laplant, Raphael Mwangi, Matthew J. Maurer, Jason R. Young, William R. Macon, Rebecca L. King, Yucai Wang, James R. Cerhan, Andrew L. Feldman, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Stephen M. Ansell, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski

Blood (2021) 138 (Supplement 1): 2508.

https://doi.org/10.1182/blood-2021-151276

Published: 2021

Journal Articles

Time to Refractory Status Defines Subsets of Primary Refractory Diffuse Large B-Cell Lymphoma with Distinct Outcomes

Allison M. Bock, Raphael Mwangi, Matthew J. Maurer, Nora Bennani, David J. Inwards, James R. Cerhan, Thomas E. Witzig, Thomas M. Habermann, Yucai Wang, Grzegorz S. Nowakowski

Blood (2021) 138 (Supplement 1): 2524.

https://doi.org/10.1182/blood-2021-146206

Published: 2021

Journal Articles

Impact of Diagnosis-to-Treatment Interval on Overall Survival in Patients with Mantle Cell Lymphoma: A National Cancer Database Analysis

Xavier Andrade-Gonzalez, Allison M. Bock, Jacqueline Wang, Antoine Saliba, Javier Munoz, David J. Inwards, Jonas Paludo, Thomas M. Habermann, Grzegorz S. Nowakowski, Yucai Wang

Blood (2021) 138 (Supplement 1): 3549.

https://doi.org/10.1182/blood-2021-151952

Published: 2021

Journal Articles

Central Nervous System Involvement By Mantle Cell Lymphoma

Nicole McLaughlin, Jonas Paludo, Yucai Wang, David J. Inwards, Nora Bennani, Gita Thanarajasingam, Jose C. Villasboas, Grzegorz S. Nowakowski, Luis F. Porrata, Carrie A. Thompson, Ivana N. Micallef, Patrick B. Johnston, Thomas E. Witzig, Thomas M. Habermann, Stephen M. Ansell

Blood (2021) 138 (Supplement 1): 2426.

https://doi.org/10.1182/blood-2021-148447

Published: 2021

Journal Articles

Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era

Yucai Wang, Melissa C. Larson, Alessia Castellino, Matthew J. Maurer, Andrew L. Feldman, Sergei Syrbu, Brian K. Link, Umar Farooq, David J. Inwards, Jonas Paludo, Thomas E. Witzig, Thomas M. Habermann, James R. Cerhan, Grzegorz S. Nowakowski

Blood (2021) 138 (Supplement 1): 2429.

https://doi.org/10.1182/blood-2021-147538

Published: 2021

Journal Articles

Autograft-Absolute Lymphocyte Count Infusion Predicts Survival in Double/Triple Hit Lymphomas Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation

Luis F. Porrata, David J. Inwards, Stephen M. Ansell, Ivana N. Micallef, Patrick B. Johnston, Jose Villasboas, Jonas Paludo, Svetomir N. Markovic

Blood (2021) 138 (Supplement 1): 1836.

https://doi.org/10.1182/blood-2021-144345

Published: 2021

Journal Articles

Improvement in Outcomes of Autologous Stem Cell Transplant in Patients with Lymphoma Older Than 70 Years: The Significance of Age in 2020s?

Kitsada Wudhikarn, Bradley K. Johnson, Jose C. Villasboas, Jonas Paludo, David J. Inwards, Luis F. Porrata, Ivana N. Micallef, Stephen M. Ansell, Patrick B. Johnston

Blood (2021) 138 (Supplement 1): 2908.

https://doi.org/10.1182/blood-2021-144507

Published: 2021

Journal Articles

Immunologic Autograft Engineering: 13 Years Follow-up

Luis F. Porrata, David J. Inwards, Stephen M. Ansell, Ivana N. Micallef, Patrick B. Johnston, Jose C. Villasboas, Jonas Paludo, Svetomir N. Markovic

Blood (2021) 138 (Supplement 1): 3936.

https://doi.org/10.1182/blood-2021-148454

Published: 2021

Journal Articles

Parsaclisib in Combination with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Preliminary Results of a Phase 1/1b Study

Yucai Wang, Betsy Laplant, Rebecca L. King, Ivana N. Micallef, Stephen M. Ansell, Han W. Tun, Madiha Iqbal, Gita Thanarajasingam, Allison C. Rosenthal, David J. Inwards, Patrick B. Johnston, Luis F. Porrata, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski

Blood (2021) 138 (Supplement 1): 1415.

https://doi.org/10.1182/blood-2021-147507

Published: 2021

Journal Articles

Impact of Novel Agents on the Outcomes of Patients with Classic Hodgkin Lymphoma That Relapsed after Autologous Stem Cell Transplant

Aung M Tun, Yucai Wang, Aasiya Matin, David J. Inwards, Patrick B. Johnston, Ivana N. Micallef, Luis F. Porrata, Jose C. Villasboas, Jonas Paludo, Han W. Tun, Allison C. Rosenthal, James R. Cerhan, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski, Stephen M. Ansell

Blood (2021) 138 (Supplement 1): 1373.

https://doi.org/10.1182/blood-2021-154038

Published: 2021

Journal Articles

Influence of Treatment Facility Type and Annual Patient Volume on Overall Survival in Patients with Mantle Cell Lymphoma: A National Cancer Database Analysis

Xavier Andrade-Gonzalez, Anuhya Kommalapati, Allison M. Bock, Jacqueline Wang, Antoine Saliba, Javier Munoz, David J. Inwards, Jonas Paludo, Thomas M. Habermann, Grzegorz S. Nowakowski, Yucai Wang

Blood (2021) 138 (Supplement 1): 1348.

https://doi.org/10.1182/blood-2021-151888

Published: 2021

Journal Articles

Outcomes of Primary Bone Diffuse Large B-Cell Lymphoma in the Rituximab Era: A Multicenter Retrospective Analysis

Blood (2021) 138 (Supplement 1): 1451.

https://doi.org/10.1182/blood-2021-145145

Published: 2021

Journal Articles

Quality of Life after Diagnosis in Survivors of Aggressive Lymphomas

Robert M. Kraft, MD, Melissa C. Larson, MS, Kathleen J. Yost, PhD, Thomas M. Habermann, MD, Matthew J. Maurer, MS, William R. Macon, MD, Umar Farooq, MD, David J. Inwards, MD, Gita Thanarajasingam, MD, Brian K. Link, MD, James R. Cerhan, MD PhD, Carrie A. Thompson, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-134897

Published: 2020

Journal Articles

Impact of Cell of Origin (COO) on Long Term Outcomes Post Autologous Hematopoietic Cell Transplant in Patients with Relapsed/ Refractory Chemotherapy Sensitive De-Novo Diffuse Large B-Cell Lymphoma (DLBCL)

Madiha Iqbal, MBBS, Yennifer Gil, Jonas Paludo, MD, Allison C. Rosenthal, D.O., Zhou Li, MS, Manuel Beltran, David J. Inwards, MD, Luis F. Porrata, MD, Ivana Micallef, MD, Jose C Villasboas, MD, Patrick B. Johnston, Stephen M. Ansell, MD PhD, Craig B. Reeder, MD, Hemant S. Murthy, MD, Vivek Roy, MD, James M. Foran, MD, Han W. Tun, MD, Mohamed A. Kharfan-Dabaja, MDMBA, Ernesto Ayala, MD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-136332

Published: 2020

NARROW

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma

Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis

Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting

Day 100 Peripheral Blood Natural Killer Cell/CD14+HLA-DR - Ratio Predicts Clinical Outcomes in Lymphoma Patients Treated with Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation

Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411

PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts

Time to Refractory Status Defines Subsets of Primary Refractory Diffuse Large B-Cell Lymphoma with Distinct Outcomes

Impact of Diagnosis-to-Treatment Interval on Overall Survival in Patients with Mantle Cell Lymphoma: A National Cancer Database Analysis

Central Nervous System Involvement By Mantle Cell Lymphoma

Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era

Autograft-Absolute Lymphocyte Count Infusion Predicts Survival in Double/Triple Hit Lymphomas Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation

Improvement in Outcomes of Autologous Stem Cell Transplant in Patients with Lymphoma Older Than 70 Years: The Significance of Age in 2020s?

Immunologic Autograft Engineering: 13 Years Follow-up

Parsaclisib in Combination with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Preliminary Results of a Phase 1/1b Study

Impact of Novel Agents on the Outcomes of Patients with Classic Hodgkin Lymphoma That Relapsed after Autologous Stem Cell Transplant

Influence of Treatment Facility Type and Annual Patient Volume on Overall Survival in Patients with Mantle Cell Lymphoma: A National Cancer Database Analysis

Outcomes of Primary Bone Diffuse Large B-Cell Lymphoma in the Rituximab Era: A Multicenter Retrospective Analysis

Quality of Life after Diagnosis in Survivors of Aggressive Lymphomas

Impact of Cell of Origin (COO) on Long Term Outcomes Post Autologous Hematopoietic Cell Transplant in Patients with Relapsed/ Refractory Chemotherapy Sensitive De-Novo Diffuse Large B-Cell Lymphoma (DLBCL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only